T 2127/16 (Anti-ADDL antibodies/MERCK) of 09.06.2020
- European Case Law Identifier
- ECLI:EP:BA:2020:T212716.20200609
- Date of decision
- 9 June 2020
- Case number
- T 2127/16
- Petition for review of
- -
- Application number
- 05820737.4
- IPC class
- C07K 16/18G01N 33/50G01N 33/68
- Language of proceedings
- English
- Distribution
- No distribution (D)
- Download
- Decision in English
- OJ versions
- No OJ links found
- Other decisions for this case
- -
- Abstracts for this decision
- -
- Application title
- Anti-ADDL antibodies and uses thereof
- Applicant name
- Merck Sharp & Dohme Corp.
Northwestern University - Opponent name
- -
- Board
- 3.3.04
- Headnote
- -
- Relevant legal provisions
- European Patent Convention Art 123(2) (2007)European Patent Convention Art 54 (2007)European Patent Convention Art 56 (2007)European Patent Convention Art 83 (2007)European Patent Convention Art 84 (2007)European Patent Convention Art 87 (2007)Rules of procedure of the Boards of Appeal Art 12(4) (2007)
- Keywords
- Inventive step - (yes)
Sufficiency of disclosure - (yes) - Catchword
- -
- Cited cases
- T 0609/02
- Citing cases
- -
Order
For these reasons it is decided that:
1. The decision under appeal is set aside.
2. The case is remitted to the examining division with the order to grant a patent on the basis of claims 1 to 8 of the main request, filed with the statement of grounds of appeal, and a description to be adapted thereto.